These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7523679)

  • 21. Chimeric HIV-1 and feline immunodeficiency virus reverse transcriptases: critical role of the p51 subunit in the structural integrity of heterodimeric lentiviral DNA polymerases.
    Amacker M; Hübscher U
    J Mol Biol; 1998 May; 278(4):757-65. PubMed ID: 9614940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Highly specific inhibitors of human immunodeficiency virus type I that are particularly targeted at the reverse transcriptase].
    de Clercq E; Snoeck R
    Pathol Biol (Paris); 1993 Mar; 41(3):230-6. PubMed ID: 7687340
    [No Abstract]   [Full Text] [Related]  

  • 23. Crystal structure of nevirapine, a non-nucleoside inhibitor of HIV-1 reverse transcriptase, and computational alignment with a structurally diverse inhibitor.
    Mui PW; Jacober SP; Hargrave KD; Adams J
    J Med Chem; 1992 Jan; 35(1):201-2. PubMed ID: 1370694
    [No Abstract]   [Full Text] [Related]  

  • 24. Continuous and discontinuous changes in the unit cell of HIV-1 reverse transcriptase crystals on dehydration.
    Esnouf RM; Ren J; Garman EF; Somers DO; Ross CK; Jones EY; Stammers DK; Stuart DI
    Acta Crystallogr D Biol Crystallogr; 1998 Sep; 54(Pt 5):938-53. PubMed ID: 9757109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
    Balzarini J; Karlsson A; Sardana VV; Emini EA; Camarasa MJ; De Clercq E
    Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6599-603. PubMed ID: 7517553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative analysis of the endogenous reverse transcriptase reactions of HIV type 1 variants with decreased susceptibility to azidothymidine and nevirapine.
    Krogstad P; Chen IS; Canon J; Rey O
    AIDS Res Hum Retroviruses; 1996 Jul; 12(11):977-83. PubMed ID: 8827213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors.
    Balzarini J; Weeger M; Camarasa MJ; De Clercq E; Uberla K
    Biochem Biophys Res Commun; 1995 Jun; 211(3):850-6. PubMed ID: 7541200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones.
    Cywin CL; Klunder JM; Hoermann M; Brickwood JR; David E; Grob PM; Schwartz R; Pauletti D; Barringer KJ; Shih CK; Sorge CL; Erickson DA; Joseph DP; Hattox SE
    J Med Chem; 1998 Jul; 41(16):2972-84. PubMed ID: 9685236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymes.
    Proudfoot JR; Hargrave KD; Kapadia SR; Patel UR; Grozinger KG; McNeil DW; Cullen E; Cardozo M; Tong L; Kelly TA
    J Med Chem; 1995 Nov; 38(24):4830-8. PubMed ID: 7490732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus.
    Mao C; Sudbeck EA; Venkatachalam TK; Uckun FM
    Antivir Chem Chemother; 1999 Sep; 10(5):233-40. PubMed ID: 10574178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
    Debyser Z; De Vreese K; Knops-Gerrits PP; Baekelandt V; Bhikhabhai R; Strandberg B; Pauwels R; Anné J; Desmyter J; De Clercq E
    Mol Pharmacol; 1993 Apr; 43(4):521-6. PubMed ID: 7682649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.
    Hopkins AL; Ren J; Esnouf RM; Willcox BE; Jones EY; Ross C; Miyasaka T; Walker RT; Tanaka H; Stammers DK; Stuart DI
    J Med Chem; 1996 Apr; 39(8):1589-600. PubMed ID: 8648598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase.
    Quan Y; Motakis D; Buckheit R; Xu ZQ; Flavin MT; Parniak MA; Wainberg MA
    Antivir Ther; 1999; 4(4):203-9. PubMed ID: 10723499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 6. 2-Indol-3-yl- and 2-azaindol-3-yl-dipyridodiazepinones.
    Kelly TA; McNeil DW; Rose JM; David E; Shih CK; Grob PM
    J Med Chem; 1997 Jul; 40(15):2430-3. PubMed ID: 9240358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure of HIV-1 reverse transcriptase/DNA complex at 7 A resolution showing active site locations.
    Arnold E; Jacobo-Molina A; Nanni RG; Williams RL; Lu X; Ding J; Clark AD; Zhang A; Ferris AL; Clark P
    Nature; 1992 May; 357(6373):85-9. PubMed ID: 1374166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.
    Das K; Sarafianos SG; Clark AD; Boyer PL; Hughes SH; Arnold E
    J Mol Biol; 2007 Jan; 365(1):77-89. PubMed ID: 17056061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
    Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
    Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Purification, characterization and crystallization of recombinant HIV-1 reverse transcriptase.
    Bhikhabhai R; Joelson T; Unge T; Strandberg B; Carlsson T; Lövgren S
    J Chromatogr; 1992 Jun; 604(1):157-70. PubMed ID: 1379251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.
    Balzarini J; Karlsson A; Vandamme AM; Pérez-Pérez MJ; Zhang H; Vrang L; Oberg B; Bäckbro K; Unge T; San-Félix A
    Proc Natl Acad Sci U S A; 1993 Aug; 90(15):6952-6. PubMed ID: 7688467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Five viral peptide-HLA-A2 co-crystals. Simultaneous space group determination and X-ray data collection.
    Garboczi DN; Madden DR; Wiley DC
    J Mol Biol; 1994 Jun; 239(4):581-7. PubMed ID: 7516439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.